Critical Care Self-Assessment Program (CCSAP) 2026 (L269036)
ACPE Numbers: Various – see listing below
Release Date: March 17, 2026
Expiration Dates: March 16, 2027
Activity Type: Application-based
CE Credits: 22.5 contact hours (BPS and ACPE)
Activity Fee: $88 (ASHP member); $132 (non-member)
Activity Overview
This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 10 learning modules (see table below) and provides up to 22.5 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCCCP recertification approved by the BPS.
Accreditation
 |
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation. |
 |
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. |
Target Audience
The target audience for CCSAP 2026 is board-certified and advanced level ambulatory care clinical pharmacists.
Recertification Credit
Board certified pharmacists are eligible to receive up to 22.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCCCP.
|
Learning Activity |
Passing Score |
Credit Information |
|
Atrial Fibrillation |
73% |
1.5 Contact Hours BPS: BCCCP |
|
Acute Ischemic Stroke and Neuroendovascular Procedures |
73% |
3 Contact Hours BPS: BCCCP |
|
Acute Respiratory Distress Syndrome |
73% |
2 Contact Hours BPS: BCCCP |
| Pain, Agitation, and Delirium |
73% |
2.5 Contact Hours BPS: BCCCP |
| Acute Issues in Obstetrics |
73% |
2 Contact Hours BPS: BCCCP |
| Thrombocytopenia in Critical Illness |
73% |
2.5 Contact Hours BPS: BCCCP |
| Necrotizing Infections |
80% |
1.5 Contact Hours BPS: BCCCP |
| Burn Injury and Multisystem Trauma |
66% |
2 Contact Hours BPS: BCCCP |
| Case Series: Vascular Emergencies |
83% |
3 Contact Hours BPS: BCCCP |
| Artificial Intelligence in Critical Care | 66% |
2.5 Contact Hours BPS: BCCCP |
Learning Objectives
Chapter: Atrial Fibrillation
ACPE #: 0217-9999-26-038-H01-P
- Apply knowledge of the definition, epidemiology, morbidity, and mortality of atrial fibrillation (AF) in patients with critical illness.
- Distinguish the mechanism and pathophysiology of AF in patients with critical illness and how it differs from the presentation seen in the community, including the different adverse clinical effects of AF in patients with critical illness.
- Develop treatment for patients with AF in different clinical scenarios, as well as in special populations with respect to the hemodynamic adverse effects of AF.
- Design prevention of thromboembolic events caused by AF in patients with critical illness, including the management of anticoagulants in special populations and various clinical scenarios.
Chapter: Acute Ischemic Stroke and Neuroendovascular Procedures
ACPE #: 0217-9999-26-039-H01-P
- Design a treatment plan for managing acute ischemic stroke (AIS) from prevention to presentation to secondary prevention.
- Distinguish the potential therapeutic differences between alteplase and tenecteplase for the treatment of AIS.
- Evaluate the pharmacotherapy needs of common neuroendovascular procedures.
- Analyze available evidence for the use of intra-arterial vasodilators for the treatment of cerebral vasospasm.
- Develop a treatment plan for special populations requiring neuroendovascular intervention.
Case Series: Acute Respiratory Distress Syndrome
ACPE #: 0217-9999-26-040-H01-P
- Evaluate emerging diagnostic strategies and biomarkers for acute respiratory distress syndrome (ARDS).
- Distinguish the impact of ventilator and oxygen-support strategies in improving outcomes in patients with ARDS.
- Assess the role of nonpharmacologic interventions in the management of ARDS.
- Critically analyze the latest evidence-based guidelines and advances in the pharmacologic management of ARDS.
Chapter: Pain, Agitation, and Delirium
ACPE #: 0217-9999-26-041-H01-P
- Apply knowledge of epidemiology, clinical significance, and guideline updates of pain, agitation, and delirium and their implications for long-term ICU outcomes.
- Design an evidence-based multimodal pain management regimen tailored to the needs of critically ill patients in the ICU.
- Design indication-based sedation strategies for critically ill patients by incorporating clinical context, patient comorbidities, and risk of adverse effects.
- Evaluate the place in therapy for emerging therapies for deep sedation in special ICU populations.
- Evaluate the evidence for established and novel pharmacotherapy agents in the prevention and treatment of ICU delirium.
Chapter: Acute Issues in Obstetrics
ACPE #: 0217-9999-26-042-H01-P
- Distinguish the physiologic changes related to pregnancy and the associated pharmacokinetic alterations of medications.
- Identify how pregnancy affects the diagnosis of common conditions in critically ill patients and their related pharmacotherapy.
- Demonstrate an understanding of obstetric emergencies and the clinical manifestations of each.
- Design a pharmacotherapy treatment plan for the critically ill patient with an obstetric emergency.
Case Series: Thrombocytopenia in Critical Illness
ACPE #: 0217-9999-26-043-H01-P
- Evaluate the primary literature and guideline recommendations for the management of heparin-induced thrombocytopenia.
- Recommend evidence-based pharmacotherapy for the management of thrombotic microangiopathies.
- Assess contemporary evidence for the management of primary immune thrombocytopenia.
- Design a treatment plan for the management of thrombocytopenia in a critically ill patient.
- Distinguish between potential causes of thrombocytopenia in a critically ill patient.
Chapter: Necrotizing Infections
ACPE #: 0217-9999-26-044-H01-P
- Distinguish the characteristics of necrotizing infections by outlining the presentation and associated outcomes.
- Analyze the classification, diagnosis, and pathogens associated with necrotizing infections in critically ill patients.
- Evaluate the antimicrobial management strategies for necrotizing infections incorporating recent literature and controversies.
- Design an antimicrobial regimen that incorporates transitions of care principles.
- Assess the role of critical care pharmacists in optimizing treatment of the disease state.
Chapter: Burn Injury and Multisystem Trauma
ACPE #: 0217-9999-26-045-H01-P
- Design an initial management strategy for the burned multisystem trauma patient according to injury severity.
- Design a plan for fluid resuscitation after significant burn injury and multisystem trauma.
- Assess signs of coagulopathy after acute burn and traumatic injuries.
- Evaluate risk-benefit of surgical intervention in the acutely burned multisystem trauma patient.
- Formulate a patient-centered nutrition plan after significant burn and traumatic injuries.
- Develop a supportive care regimen for patients with acute burn and traumatic injuries.
Case Series: Vascular Emergencies
ACPE #: 0217-9999-26-046-H01-P
- Design and implement an impulse control medication regimen for the management of patients with acute aortic syndrome.
- Justify anticoagulant and antiplatelet therapy in the management of mesenteric ischemia and extracranial cervical artery dissection.
- Evaluate the role of localized thrombolytic and vasodilator therapy in patients with acute limb ischemic injuries.
- Develop a course of treatment for acute pulmonary embolism, taking into consideration risk stratification and response to therapy.
Chapter: Artificial Intelligence in Critical Care
ACPE #: 0217-9999-26-047-H01-P
- Assess the potential roles for artificial intelligence (AI) applications in the realm of critical care medicine.
- Judge the potential utility of a model based on design and performance characteristics.
- Apply AI principles to relevant domains in critical care medicine.
- Detect potential concerns with the design or performance of reported model based on information provided.
- Evaluate AI tools based on reported qualities and metrics.
- Analyze the future landscape of AI applications in critical care to determine potential impacts on pharmacy practice, as well as potential roles for pharmacists in the design, assessment, implementation, and monitoring of AI tools.
Faculty
Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Consultancies: Zachary Smith (Merck, Johnson & Johnson); Lisa Hall Zimmerman (SCCM [two consultancies], American College of Osteopathic Surgeons [spouse or significant other]; Adrian Wong (ScholarRX); Eric G. Johnson (Wolters Kluwer); Nicholas Farina (SCCM Michigan Chapter)
Grants: Matthew A. Wanat (Texas Health and Human Services via SAMHSA); Stephen H. Rappaport (ACCP [two grants]; ASHP) David E. Zimmerman (ADMA Biologics)
Honoraria: Zachary Smith (Pharmacy Times)
Methods and CE Requirements
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Development
ACCP and ASHP collaborate on critical care pharmacy activities.